Objective: To evaluate the safety, feasibility and effectiveness of a treatment for snoring using permanent palatal implants.
Material And Methods: This was a prospective, non-randomized study involving 35 healthy patients (26 males, 9 females) referred for treatment of habitual snoring. A baseline medical examination, an evaluation of snoring-related subjective symptoms and an overnight sleep analysis were performed. Three PET implants were placed in the palate of each patient using a new delivery device under local anaesthesia. The patients were followed by means of office visits at 2-3, 14, 30 and 90 days postoperatively, at which discomfort, pain, adverse events and changes in snoring-related parameters were recorded.
Results: The average time required for the procedure was 8 min; 23% of the patients required no postoperative analgesia; the average consumption of analgesic was 125 mg of diclofenac and the average duration of analgesia was 1.5 days after the procedure. No bleeding, haematoma or infection were observed. Two of the implants were extruded; both of these patients experienced a satisfactory reduction in snoring intensity and no replacements were necessary. The mean reduction in snoring intensity was 51%, with the visual analogue scale score evaluated by the bed partner falling from 7.3 to 3.6 (p<0.001). The Epworth Sleepiness Score dropped from 9.3 to 4.6 (p<0.001). In total, 86% of the bed partners and 89% of the patients recommended the procedure.
Conclusion: The new palatal implant system is safe and is associated with low morbidity. It is a fast, simple and effective treatment for snoring.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/00016480310017090 | DOI Listing |
Int J Surg Case Rep
December 2024
Department of Internal medicine, Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia.
Introduction And Importance: Chordoma is an uncommon malignant tumor that originates from the remnants of the primitive notochord in the embryo. They account for 1 % of intracranial tumors and 4 % of primary bone tumors. It is a locally aggressive tumor with a low risk of metastasis.
View Article and Find Full Text PDFJ Pers Med
December 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea.
One prior study revealed that a newly developed auto-titrating mandibular advancement device (AMAD) could potentially enhance polysomnographic outcomes in individuals with obstructive sleep apnea (OSA). However, evidence regarding its impact on autonomic nervous system dysregulation in OSA remains limited. In this study, we aimed to compare the effects of conventional mandibular advancement devices (MADs) and AMDA on autonomic function.
View Article and Find Full Text PDFNat Sci Sleep
December 2024
Department of Cardiovasology, the Traditional Chinese Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, People's Republic of China.
Purpose: Intermittent hypoxia (IH), a defining feature of obstructive sleep apnea (OSA), is associated with heart damage and linked to transient receptor potential canonical channel 5 (TRPC5). Nonetheless, the function of TRPC5 in OSA-induced cardiac injury remains uncertain. For this research, we aimed to explore the role and potential mechanism of TRPC5 in cardiomyocyte injury induced by intermittent hypoxia.
View Article and Find Full Text PDFAm J Otolaryngol
December 2024
Federal Hospital of Bonsucesso, Rio de Janeiro, Brazil.
Introduction: Intranasal mometasone and oral montelukast have been found to be effective for adenoid hypertrophy in children. We aimed to compare the efficacy of combination therapy of mometasone and montelukast versus mometasone alone for adenoid hypertrophy in children.
Methods: Following PRISMA guidelines, we systematically searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.
BMC Oral Health
December 2024
School/Hospital of Stomatology, Zhejiang Chinese Medical University, Hangzhou, China.
Objective: A preliminary clinical evaluation of the efficacy, comfort, and adverse reactions of two mandibular advancement devices (MADs) in the treatment of Obstructive Sleep Apnea (OSA).
Methods: Forty patients with mild-to-severe OSA were recruited and randomly divided into two groups. They were treated with Shark-fin or Silensor MAD, respectively.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!